Scientific illustration depicting the TMEM175 lysosomal ion channel preventing over-acidification and toxic buildup in neurons, relevant to Parkinson’s disease research.
Scientific illustration depicting the TMEM175 lysosomal ion channel preventing over-acidification and toxic buildup in neurons, relevant to Parkinson’s disease research.
Image generated by AI

Study links lysosomal ion channel TMEM175 to protection against over-acidification, with implications for Parkinson’s research

Image generated by AI
Fact checked

Researchers at LMU Munich, Bonn-Rhein-Sieg University of Applied Sciences, TU Darmstadt and Nanion Technologies report that the lysosomal ion channel TMEM175 helps prevent excessive acidification inside lysosomes, a malfunction that the team says could contribute to toxic buildup associated with Parkinson’s disease. The findings were reported in the Proceedings of the National Academy of Sciences.

A team from Bonn-Rhein-Sieg University of Applied Sciences (H-BRS), Ludwig Maximilian University of Munich (LMU Munich), TU Darmstadt and Nanion Technologies has reported new evidence clarifying how the lysosomal ion channel TMEM175 influences acidity in lysosomes—membrane-bound compartments that break down cellular waste.

Lysosomes need an acidic interior to degrade macromolecules into reusable building blocks. According to the researchers, this acidity is generated by a protein that pumps protons (H+) into lysosomes, while additional proteins in the lysosomal membrane help keep the pH within an optimal range.

In a study described by LMU Munich in a university news release and reposted by ScienceDaily, the scientists say TMEM175 acts as an “overflow valve” that helps prevent lysosomes from becoming too acidic. The release says the work addresses a long-running debate over whether TMEM175 primarily conducts potassium ions or protons, reporting that the channel can conduct both and that its behavior changes depending on luminal acidity.

The collaboration was led by pharmacologist Professor Christian Grimm (LMU Munich) and Dr. Oliver Rauh (H-BRS), according to the same release. The researchers said they relied largely on patch-clamp measurements—an electrophysiology method used to characterize ion flow through channels—to show that TMEM175 can sense when lysosomal acidity reaches a critical state and adjust proton flow through the channel.

In the release, Rauh is quoted as saying the study establishes a “decisive” role for TMEM175 in this process and calling the protein unusual among ion channels. “We’ve now been able to demonstrate that TMEM175 not only conducts potassium ions, but also protons, and is thus directly involved in the regulation of pH … in the interior of lysosomes,” he said.

The researchers also argued that mutations affecting TMEM175 can disrupt pH regulation and impair lysosomal degradation, potentially contributing to toxic protein buildup and neuronal cell death. The news release links these effects to Parkinson’s disease and other neurodegenerative conditions and describes TMEM175 as a potential target for drug development.

The study was published in the Proceedings of the National Academy of Sciences under the title “Proton-selective conductance and gating of the lysosomal cation channel TMEM175,” with the DOI 10.1073/pnas.2503909123, and a publication date of January 14, 2026.

Related Articles

A scientist in a lab examines cellular images representing lysosome activation in progeria research.
Image generated by AI

Lysosome activation clears progerin and eases cellular aging in progeria, study finds

Reported by AI Image generated by AI Fact checked

Scientists in China report that repairing defects in lysosomes—the cell’s waste‑disposal hubs—accelerated clearance of progerin in patient cells and reduced markers of cellular aging, pointing to a potential therapeutic target for Hutchinson‑Gilford progeria syndrome.

Researchers at Sweden’s Karolinska Institutet and Japan’s RIKEN Center for Brain Science report that two somatostatin receptors, SST1 and SST4, jointly regulate levels of neprilysin—an enzyme that breaks down amyloid-beta—in the hippocampus. In mouse models, activating the receptors raised neprilysin, reduced amyloid-beta buildup and improved memory-related behavior, the team said.

Reported by AI

Researchers at UCLA Health and UC San Francisco have identified a natural defense mechanism in brain cells that helps remove toxic tau protein, potentially explaining why some neurons resist Alzheimer's damage better than others. The study, published in Cell, used CRISPR screening on lab-grown human neurons to uncover this system. Findings suggest new therapeutic avenues for neurodegenerative diseases.

Researchers have demonstrated that restoring levels of a key brain energy molecule can reverse advanced Alzheimer's disease in mouse models, repairing damage and restoring cognitive function. The study, published on December 22, challenges the long-held view that the condition is irreversible. Findings from human brain tissue support the approach's potential relevance to patients.

Reported by AI

Researchers have uncovered how amyloid beta and inflammation may both trigger synapse pruning in Alzheimer's disease through a common receptor, potentially offering new treatment avenues. The findings challenge the notion that neurons are passive in this process, showing they actively erase their own connections. Led by Stanford's Carla Shatz, the study suggests targeting this receptor could preserve memory more effectively than current amyloid-focused drugs.

Researchers report that reduced ATP signaling in the dorsal hippocampus of male mice, driven by changes in the protein connexin 43, can trigger both depression- and anxiety-like behaviors. The study, published in The Journal of Neuroscience, finds that chronic stress lowers extracellular ATP and connexin 43 levels, that experimentally reducing the protein induces similar behaviors even without stress, and that restoring it in stressed animals improves behavioral signs of distress.

Reported by AI

An international team of researchers has identified a previously unknown type of diabetes in newborns caused by mutations in the TMEM167A gene. This rare condition leads to both high blood sugar and neurological issues like epilepsy and microcephaly. The findings, published in a leading medical journal, could enhance understanding of insulin production in broader diabetes research.

 

 

 

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline